scholarly journals A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor

Blood ◽  
2014 ◽  
Vol 123 (15) ◽  
pp. 2308-2316 ◽  
Author(s):  
David H. McDermott ◽  
Qian Liu ◽  
Daniel Velez ◽  
Lizbeeth Lopez ◽  
Sandra Anaya-O’Brien ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Low Dose ◽  
Phase 1 ◽  
Cxcr4 Antagonist ◽  
Phase 1 Clinical Trial ◽  
Dose Treatment ◽  
Whim Syndrome ◽  
Key Points

Key Points Plerixafor can be given safely to WHIM syndrome patients twice daily for a 6-month period and appears promising as a treatment.

scholarly journals A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

Blood ◽  
2016 ◽  
Vol 127 (4) ◽  
pp. 411-419 ◽  
Author(s):  
Harriet S. Walter ◽  
Simon A. Rule ◽  
Martin J. S. Dyer ◽  
Lionel Karlin ◽  
Ceri Jones ◽  
...  
Keyword(s):  
Clinical Trial ◽  
B Cell ◽  
Dose Escalation ◽  
Phase 1 ◽  
B Cell Malignancies ◽  
Dose Escalation Study ◽  
Phase 1 Clinical Trial ◽  
Human Dose ◽  
Key Points ◽  
Btk Inhibitor

Key Points We report a first-in-human dose-escalation study in relapsed/refractory B-cell malignancies with the potent BTK inhibitor ONO/GS-4059. ONO/GS-4059 induced clinically durable responses in relapsed/refractory B-cell malignancies without significant toxicities.

scholarly journals Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease

Blood ◽  
2018 ◽  
Vol 131 (25) ◽  
pp. 2836-2845 ◽  
Author(s):  
Myrna R. Nahas ◽  
Robert J. Soiffer ◽  
Haesook T. Kim ◽  
Edwin P. Alyea ◽  
Jon Arnason ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Graft Versus Host Disease ◽  
Therapeutic Approach ◽  
Phase 1 ◽  
Phase 1 Clinical Trial ◽  
Graft Versus Host ◽  
Costimulatory Blockade ◽  
Key Points ◽  
Novel Therapeutic ◽  
Steroid Refractory

Key Points Costimulatory blockade using abatacept represents a novel therapeutic approach for the treatment of cGVHD. Abatacept resulted in a clinical response in 44% of patients with both decreased prednisone use and T-cell PD-1 expression in responders.

scholarly journals NEW ANTIVIRAL DRUG TRIAZAVIRIN. RESULTS OF PHASE 1 CLINICAL TRIAL

2013 ◽  
Vol 18 (5) ◽  
pp. 20-26
Author(s):  
E. G Deeva ◽  
Leg Ivanovich Kiselev ◽  
Tatjana Ilinichna Melnikova ◽  
Aram Arutjunovich Shaldzhan ◽  
Petr Alexeevich Nekrasov ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Adverse Reactions ◽  
Phase 1 ◽  
Antiviral Drug ◽  
Systemic Exposure ◽  
Two Phase ◽  
Drug Study ◽  
Phase 1 Clinical Trial ◽  
Dosage Frequency

In the work there are presented results of the study of the pharmacokinetics, tolerability and safety of a new anti-influenza preparation Triazavirin in several dose regimes, performed in 30 volunteers. There were no recorded adverse reactions associated with the administration of the drug. Study of the pharmacokinetics showed that the maximum concentration of Triazavirin in blood plasma is achieved on average 1 - 1.5 hours after, the curve of decreasing concentrations is two-phase, half-life elimination period in the first phase is 0.5 - 1.4 hour. It is impossible to exclude polymorphic character of metabolism. The extent of systemic exposure depends on the dosage frequency more than the dose of the drug. In this case, there was no noted significant accumulation in long-term use. In the study Triazavirin was well tolerated by all participants in all the studied dose regimes. The preferred regime, providing the maintenance of an effective and safe concentrations is recognized as dosage of the 250 mg twice a day.

scholarly journals Efficacy of Pulsed Low-Dose-Rate Reirradiation: Results From a Phase 1 Clinical Trial

2016 ◽  
Vol 96 (2) ◽  
pp. S147
Author(s):  
J.E. Meyer ◽  
T.J. Galloway ◽  
K. Ruth ◽  
E.A. Ross ◽  
M.K. Buyyounouski ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Dose Rate ◽  
Low Dose ◽  
Phase 1 ◽  
Phase 1 Clinical Trial ◽  
Low Dose Rate
Sign in / Sign up

Export Citation Format

Share Document